0.787

3.42% -0.0279

Sangamo Therapeutics Inc (SGMO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.8149

Offen:

$0.8

24-Stunden-Volumen:

1.98M

Relative Volume:

0.31

Marktkapitalisierung:

$165.39M

Einnahmen:

$52.29M

Nettoeinkommen (Verlust:

$-134.84M

KGV:

-1.0493

EPS:

-0.75

Netto-Cashflow:

$-117.11M

1W Leistung:

+11.54%

1M Leistung:

-6.22%

6M Leistung:

-47.53%

1J Leistung:

+56.46%

1-Tages-Spanne:

$0.77

$0.8299

1-Wochen-Bereich:

$0.70

$0.84

52-Wochen-Spanne:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Firmenname

Sangamo Therapeutics Inc

Sektor

Healthcare (1154)

Branche

Biotechnology (677)

Telefon

(510) 970-6000

Adresse

501 CANAL BLVD., RICHMOND, CA

Mitarbeiter

183

Twitter

@sangamotx

Nächster Verdiensttermin

2025-03-17

Neueste SEC-Einreichungen

SGMO's Discussions on Twitter

Vergleichen Sie SGMO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SGMO Sangamo Therapeutics Inc	0.787	165.39M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Hochstufung	Truist	Hold → Buy
2024-12-10	Bestätigt	H.C. Wainwright	Buy
2023-11-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Herabstufung	BofA Securities	Neutral → Underperform
2023-02-27	Hochstufung	Wedbush	Neutral → Outperform
2023-01-06	Herabstufung	BofA Securities	Buy → Neutral
2022-06-13	Fortgesetzt	Wedbush	Neutral
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-07	Fortgesetzt	Guggenheim	Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-12-16	Fortgesetzt	H.C. Wainwright	Buy
2020-09-08	Eingeleitet	BofA Securities	Buy
2020-07-07	Eingeleitet	SunTrust	Buy
2019-08-26	Eingeleitet	H.C. Wainwright	Buy
2018-11-14	Herabstufung	JP Morgan	Overweight → Neutral
2018-11-09	Herabstufung	Guggenheim	Buy → Neutral
2018-10-10	Eingeleitet	Guggenheim	Buy
2018-06-20	Eingeleitet	BofA/Merrill	Buy
2017-11-15	Hochstufung	Piper Jaffray	Neutral → Overweight
2017-06-22	Fortgesetzt	Jefferies	Buy
2016-11-01	Herabstufung	Wedbush	Outperform → Neutral
2016-10-19	Herabstufung	Piper Jaffray	Overweight → Neutral
2015-12-04	Eingeleitet	Wells Fargo	Outperform
2015-10-23	Fortgesetzt	Jefferies	Buy
2013-05-03	Eingeleitet	BioLogic Equity Research	Sell
2011-02-23	Bestätigt	JMP Securities	Mkt Outperform
2010-07-29	Bestätigt	Wedbush	Outperform
2009-10-19	Eingeleitet	Brean Murray	Sell
2009-10-07	Bestätigt	Leerink Swann	Outperform
2009-08-25	Bestätigt	JMP Securities	Mkt Outperform

Alle ansehen

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

Apr 22, 2025

Form 4Statement of changes in beneficial ownership of securities - ADVFN

Apr 22, 2025

Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025

Apr 13, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025

Apr 02, 2025